You have free access to this content

Cancer

Cover image for Cancer

1 April 2010

Volume 116, Issue 7

Pages 1617–1840

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editiorials
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    8. Erratum
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
  2. Editiorials

    1. Top of page
    2. CancerScope
    3. Editiorials
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    8. Erratum
    1. You have free access to this content
      Radiation versus resection for Merkel cell carcinoma (pages 1620–1622)

      Christopher K. Bichakjian, Daniel G. Coit and Sandra L. Wong

      Article first published online: 27 JAN 2010 | DOI: 10.1002/cncr.24931

      A report by Fang et al on lymph node disease in patients with Merkel cell carcinoma suggests that radiation monotherapy is an effective modality for regional disease control compared with lymphadenectomy. However, the selection bias inherent in retrospective studies must be considered before changing practice patterns.

  3. Editorials

    1. Top of page
    2. CancerScope
    3. Editiorials
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    8. Erratum
    1. You have free access to this content
      Tumor progression by immune evasion in melanoma : Role of the programmed cell death-1/programmed cell death-1 ligand 1 interaction (pages 1623–1625)

      Mohammed Kashani-Sabet

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.24909

      In this editorial, the author reviews evidence supporting the role of the programmed cell death-1/programmed cell death-1 ligand 1 (PD-L1) interaction in the progression of melanoma and the role of PD-L1 as a potential prognostic factor for melanoma.

    2. You have free access to this content
      Is ionizing radiation responsible for the increasing incidence of thyroid cancer? (pages 1626–1628)

      Yuri E. Nikiforov

      Article first published online: 11 FEB 2010 | DOI: 10.1002/cncr.24889

      The dose of exposure to ionizing radiation appears to correlate with increased risk of thyroid microcarcinoma. Can ionizing radiation be a factor contributing to the increasing incidence of thyroid cancer around the world?

  4. Review Articles

    1. Top of page
    2. CancerScope
    3. Editiorials
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    8. Erratum
    1. You have free access to this content
      Fyn : A novel molecular target in cancer (pages 1629–1637)

      Yoshihito D. Saito, Ana R. Jensen, Ravi Salgia and Edwin M. Posadas

      Article first published online: 11 FEB 2010 | DOI: 10.1002/cncr.24879

      Fyn is 1 of the 9 identified Src kinases that is particularly dysregulated in cancer. It appears to play a prominent role in disease progression and metastasis and this may impact therapeutic strategies involving Src kinase inhibition.

    2. You have free access to this content
      Killing tumor cells through their surface β2-microglobulin or major histocompatibility complex class I molecules (pages 1638–1645)

      Jing Yang and Qing Yi

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.24953

      Antibodies against β2-microglobulin (β2M)/major histocompatibility complex (MHC) class I molecules exhibited tumoricidal activity on several tumor cells through surface β2M/MHC class I molecules and their associated proapoptotic signaling pathways in preclinical studies. The results of this review indicated that targeting β2M/MHC class I molecules or their associated signaling pathways by using specific monoclonal antibodies or other agents is a potential novel therapeutic strategy for treating cancers.

  5. Original Articles

    1. Top of page
    2. CancerScope
    3. Editiorials
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    8. Erratum
    1. Disease Site

      Endocrine Disease
      You have free access to this content
      Papillary microcarcinoma of the thyroid among atomic bomb survivors : Tumor characteristics and radiation risk (pages 1646–1655)

      Yuzo Hayashi, Frederic Lagarde, Nobuo Tsuda, Sachiyo Funamoto, Dale L. Preston, Kojiro Koyama, Kiyohiko Mabuchi, Elaine Ron, Kazunori Kodama and Shoji Tokuoka

      Article first published online: 29 JAN 2010 | DOI: 10.1002/cncr.24872

      Exposure to low-to-moderate doses of ionizing radiation appears to be associated with an elevated risk of thyroid papillary microcarcinoma, even when exposure occurs during adulthood.

    2. Gastrointestinal Disease
      You have free access to this content
      Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction (pages 1656–1663)

      Jaffer A. Ajani, Arlene M. Correa, Garrett L. Walsh, Ritsuko Komaki, Jeffrey H. Lee, Ara A. Vaporciyan, David C. Rice, James C. Yao, Dipen M. Maru, Wayne L. Hofstetter, Alexandria T. Phan and Stephen G. Swisher

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.24935

      For 55 patients with potentially resectable carcinoma of the esophagus, a novel nonplatinum 3-drug combination was used with radiation to assess toxicities and the pathologic complete response rate. These data suggested that a fluoropyrimidine with or without another cytotoxic (from any class of cytotoxics) can form a baseline regimen to which biologics can be added.

    3. You have free access to this content
      Effectiveness of a patient- and practice-level colorectal cancer screening intervention in health plan members : Design and baseline findings of the CHOICE trial (pages 1664–1673)

      Carmen Lewis, Michael Pignone, Laura A. Schild, Tracy Scott, Andrea Winquist, Barbara K. Rimer and Karen Glanz

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.24962

      The unique CHOICE (Communicating Health Options through Information and Cancer Education) trial design allows the assessment of colorectal cancer test completion via claims data for trial participants as well as nonrespondents. The results demonstrate the effect of 2 combined evidence-based interventions implemented in community settings among health plan members.

    4. You have free access to this content
      Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis (pages 1674–1680)

      Thomas Liggett, Anatoliy Melnikov, Qi-long Yi, Charles Replogle, Randall Brand, Karen Kaul, Mark Talamonti, Ross A. Abrams and Victor Levenson

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.24893

      By using methylation analysis of cell-free plasma DNA from blood, the authors developed a composite biomarker for distinguishing between pancreatic cancer and chronic pancreatitis that may be useful for differential detection of these diseases in a gastrointestinal clinic. To the authors' knowledge, this is the first report demonstrating that neoplastic and inflammatory diseases of the same organ can be detected differentially by a simple blood analysis.

    5. You have free access to this content
      Progress for resectable cancer? : A population-based assessment of US practices (pages 1681–1690)

      Jessica P. Simons, Sing Chau Ng, Theodore P. McDade, Zheng Zhou, Craig C. Earle and Jennifer F. Tseng

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.24918

      Despite reports of improved outcomes after resection for pancreatic cancer, many patients do not receive all elements ofguideline-directed care. Adherence is improving, but the survival benefit is gradual.

      Corrected by:

      Erratum: Erratum: Progress for resectable cancer?: A population-based assessment of US practices

      Vol. 116, Issue 10, 2503, Article first published online: 24 FEB 2010

    6. You have free access to this content
      Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients (pages 1691–1698)

      Frank Sinicrope, Nathan R. Foster, Daniel J. Sargent, Stephen N. Thibodeau, Thomas C. Smyrk and Michael J. O'Connell

      Article first published online: 22 FEB 2010 | DOI: 10.1002/cncr.24913

      A predictive model incorporating clinical and pathological variables can increase the efficiency of testing for defective DNA mismatch repair in sporadic colon cancer patients for use in clinical decisions.

    7. Genitourinary Disease
      You have free access to this content
      Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer (pages 1699–1708)

      Mark Garzotto, Celestia S. Higano, Catherine O'Brien, Brooks L. S. Rademacher, Nicole Janeba, Ladan Fazli, Paul H. Lange, Stephen Lieberman and Tomasz M. Beer

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.24960

      Preoperative chemotherapy with docetaxel and mitoxantrone in patients with clinically localized high-risk prostate cancer is feasible, with approximately half of the patients remaining free of disease recurrence at 5 years. Pretreatment serum prostate-specific antigen, lymph node involvement, and postchemotherapy tissue vascular endothelial growth factor expression were independent predictors of early recurrence.

    8. Head and Neck Disease
      You have free access to this content
      Two members of the SIBLING family of proteins, DSPP and BSP, may predict the transition of oral epithelial dysplasia to oral squamous cell carcinoma (pages 1709–1717)

      Kalu U. E. Ogbureke, Rafik A. Abdelsayed, Harvey Kushner, Li Li and Larry W. Fisher

      Article first published online: 22 FEB 2010 | DOI: 10.1002/cncr.24938

      Bone sialoprotein (BSP) and dentin sialophosphoprotein (DSPP) are excellent candidate markers for successful oral premalignant lesions (OPL) surgical intervention and may be predictors of OPL transition to oral squamous cell carcinomas. Whereas DSPP expression may signal potential transition, up-regulation of BSP in dysplastic OPLs may be protective.

    9. You have free access to this content
      Pharyngoesophageal reconstruction with the anterolateral thigh flap after total laryngopharyngectomy (pages 1718–1724)

      Peirong Yu, Matthew M. Hanasono, Roman J. Skoracki, Donald P. Baumann, Jan S. Lewin, Randal S. Weber and Geoffrey L. Robb

      Article first published online: 29 JAN 2010 | DOI: 10.1002/cncr.24947

      The authors' experience with pharyngoesophageal reconstruction using the anterolateral thigh flap achieved superior clinical and functional outcomes and significantly less donor site morbidity than traditional methods.

    10. Hematologic Malignancies
      You have free access to this content
      Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study (pages 1725–1732)

      Xavier Thomas, Emmanuel Raffoux, Aline Renneville, Cecile Pautas, Stephane de Botton, Christine Terre, Claude Gardin, Sandrine Hayette, Claude Preudhomme and Herve Dombret

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.24943

      Sensitization of leukemic cells and their progenitors by granulocytic hematopoietic growth factors appears as a plausible strategy for improving the outcome of younger patients with newly diagnosed acute myeloid leukemia. Patients with poor-prognosis fms-like tyrosine kinase-3 internal duplications or mixed-lineage leukemia genen rearrangement might be a good target population to further investigate priming strategies.

    11. Hepatobiliary Disease
      You have free access to this content
      In-hospital mortality from liver resection for hepatocellular carcinoma : A simple risk score (pages 1733–1738)

      Jessica P. Simons, Sing Chau Ng, Joshua S. Hill, Shimul A. Shah, Zheng Zhou and Jennifer F. Tseng

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.24904

      There is a wide spectrum of disease burden in hepatocellular carcinoma accompanied by several options for surgical management, but the associated mortality of such procedures has not been well defined. In this study, the authors established that an integer-based risk score can be used to predict in-hospital mortality after surgery for hepatocellular carcinoma, and it may be useful for preoperative risk stratification and patient counseling.

    12. Lung Disease
      You have free access to this content
      Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model (pages 1739–1750)

      Xiaoyu Xu and Glenn D. Prestwich

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.24907

      First, we optimize a three-dimensional encapsulation system for A549 cells that permits complete experimental control over the composition of the extracellular matrix used for encapsulation. Second, we demonstrate that a lysophosphatidic acid (LPA) receptor antagonist/autotaxin inhibitor dramatically reduces tumor volume and tumor vascularity, thus validating the LPA signaling pathway as a clinical target for the treatment of lung cancer.

    13. Melanoma
      You have free access to this content
      A phase 2 pilot trial of low-dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma (pages 1751–1756)

      Rupal S. Bhatt, Jaime Merchan, Robert Parker, Hua-Kang Wu, Liang Zhang, Virginia Seery, John V. Heymach, Michael B. Atkins, David McDermott and Vikas P. Sukhatme

      Article first published online: 29 JAN 2010 | DOI: 10.1002/cncr.24902

      Patients with metastatic melanoma were treated with metronomic doses of paclitaxel and celecoxib. The results demonstrated that this combination can lead to disease stabilization in a proportion of patients.

    14. You have free access to this content
      Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma (pages 1757–1766)

      Ryosuke Hino, Kenji Kabashima, Yu Kato, Hiroaki Yagi, Motonobu Nakamura, Tasuku Honjo, Taku Okazaki and Yoshiki Tokura

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.24899

      The current results indicated that programmed cell death-1 ligand 1 expression is correlated with tumor proliferation and patient survival. These data indicated the immunosuppressive aspect of melanoma.

    15. You have full text access to this OnlineOpen article
      Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting : Lymphocyte count after 2 doses correlates with survival (pages 1767–1775)

      Geoffrey Y. Ku, Jianda Yuan, David B. Page, Sebastian E. A. Schroeder, Katherine S. Panageas, Richard D. Carvajal, Paul B. Chapman, Gary K. Schwartz, James P. Allison and Jedd D. Wolchok

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.24951

      This description of 51 patients with advanced, treatment-refractory melanoma who were enrolled in a compassionate use trial of ipilimumab at Memorial Sloan-Kettering Cancer Center confirms that ipilimumab is active in this disease setting. In addition, the results suggest that the absolute lymphocyte count after 2 ipilimumab treatments (at Week 7) highly correlates with the rate of clinical benefit at Week 24 and overall survival.

    16. Neuro-Oncology
      You have free access to this content
      Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas (pages 1776–1782)

      Fabio M. Iwamoto, Teri N. Kreisl, Lyndon Kim, J. Paul Duic, John A. Butman, Paul S. Albert and Howard A. Fine

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.24957

      Glioma cells secrete glutamate and also express AMPA glutamate receptors, which contribute to proliferation, migration, and neurotoxicity of malignant gliomas. A phase 2 trial of talampanel, an AMPA receptor inhibitor, was conducted. Thirty patients with recurrent malignant glioma were enrolled, and although talampanel was well‒tolerated, it demonstrated no significant tumor activity as a single agent in this population.

    17. Skin
      You have free access to this content
      Radiation monotherapy as regional treatment for lymph node-positive Merkel cell carcinoma (pages 1783–1790)

      L. Christine Fang, Bianca Lemos, James Douglas, Jayasri Iyer and Paul Nghiem

      Article first published online: 16 FEB 2010 | DOI: 10.1002/cncr.24919

      Lymph lymph node irradiation alone to positive regional lymph nodes is reported to confer an excellent regional control rate that is comparable to completion lymphadenectomy for both microscopic and palpable lymph node-positive Merkel cell carcinoma. Finding that their efficacy was similar, the choice between these lymph node therapies was based on the clinical scenario and anticipated side effect profiles.

    18. Discipline

      Disparities Research
      You have free access to this content
      The impact of breast reconstruction on the delivery of chemotherapy (pages 1791–1800)

      Amy K. Alderman, E. Dale Collins, Anne Schott, Melissa E. Hughes, Rebecca A. Ottesen, Richard L. Theriault, Yu-Ning Wong, Jane C. Weeks, Joyce C. Niland and Stephen B. Edge

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.24891

      Immediate postmastectomy breast reconstruction does not appear to lead to the omission of chemotherapy, but it is associated with a modest, but statistically significant, delay in initiating treatment. For most, it is unlikely that this delay has any clinical significance.

    19. You have free access to this content
      Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma (pages 1801–1809)

      Jeanette C. Yu, Alfred I. Neugut, Shuang Wang, Judith S. Jacobson, Lauren Ferrante, Vandana Khungar, Emerson Lim, Dawn L. Hershman, Robert S. Brown Jr and Abby B. Siegel

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.24936

      Black patients and Medicaid recipients with hepatocellular carcinoma are much less likely than white and privately insured patients to receive a liver transplant. Those who did not receive a transplant were 3 times as likely as transplant recipients to die, but race and insurance were not independently predictive of mortality.

    20. Psychosocial Oncology
      You have free access to this content
      Anxiety disorders in advanced cancer patients : Correlates and predictors of end-of-life outcomes (pages 1810–1819)

      Ryan Spencer, Matthew Nilsson, Alexi Wright, William Pirl and Holly Prigerson

      Article first published online: 24 FEB 2010 | DOI: 10.1002/cncr.24954

      Anxiety disorders are more likely to occur in women than in men and in younger patients compared with older patients with advanced cancer. Anxiety disorders in patients with advanced cancer also are associated with decreased physical performance status and more difficulties in the physician-patient relationship.

    21. Radiation Oncology
      You have free access to this content
      The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy (pages 1820–1826)

      Kevin S. Choe, David Correa, Ashesh B. Jani and Stanley L. Liauw

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.24890

      A substantial body of preclinical evidence describes the antineoplastic effect of anticoagulation agents, although the limited data from clinical studies have been mixed. In the current study, patients with prostate cancer who received radiotherapy with curative intent, the use of anticoagulants, including aspirin, warfarin, and clopidogrel, was associated with an improvement in biochemical control, especially for those with high-risk disease.

    22. Symptom Control and Palliative Care
      You have free access to this content
      Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication (pages 1827–1837)

      Salvatore Siena, Robert Glynne-Jones, Antoine Adenis, Josef Thaler, Peter Preusser, Enrique Aranda Aguilar, Matti S. Aapro, Anja H. Loos, Regina Esser and Hansjochen Wilke

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.24945

      The current article presents a post hoc analysis of data from a European prelicense study of a monoclonal antibody, Erbitux (cetuximab), where the incidence of infusion-related reactions according to the type of prophylactic premedication administered before cetuximab infusion was investigated. Patients who received both an antihistamine and a corticosteroid had a reduced frequency of such reactions compared with those who received antihistamine alone, and the type of premedication did not impact treatment efficacy.

  6. Correspondence

    1. Top of page
    2. CancerScope
    3. Editiorials
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    8. Erratum
    1. You have free access to this content
    2. You have free access to this content
  7. Erratum

    1. Top of page
    2. CancerScope
    3. Editiorials
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    8. Erratum
    1. You have free access to this content
      Erratum (page 1840)

      Article first published online: 8 FEB 2010 | DOI: 10.1002/cncr.25026

      This article corrects:

SEARCH

SEARCH BY CITATION